DCC 2618

Drug Profile

DCC 2618

Alternative Names: DCC2618

Latest Information Update: 21 Sep 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Deciphera Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Platelet derived growth factor alpha receptor antagonists; Proto-oncogene protein c-kit expression inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastrointestinal stromal tumours; Glioblastoma; Anaplastic astrocytoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Gastrointestinal stromal tumours
  • Phase I Glioblastoma; Systemic mastocytosis

Most Recent Events

  • 18 Sep 2018 Deciphera Pharmaceuticals announces intention to register and launch DCC 2618
  • 17 Apr 2018 Preclinical data in Gastrointestinal stromal tumors (GIST) presented at the 2018 American Association for Cancer Research Annual Meeting (AACR-2018)
  • 16 Apr 2018 Pharmacokinetics data from a phase I trial in Gastrointestinal stromal tumours presented at the 109th Annual Meeting of the American Association for Cancer Research (AACR-2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top